ALPS Medical Breakthroughs ETF (SBIO)

Assets	$136.05M
Expense Ratio	0.50%
PE Ratio	n/a
Shares Out	2.53M
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	25,140
Open	55.18
Previous Close	55.06
Day's Range	53.55 - 55.18
52-Week Low	23.32
52-Week High	55.44
Beta	0.81
Holdings	89
Inception Date	Dec 31, 2014

About SBIO

Fund Home Page

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.

• Asset Class: Equity
• Category: Health
• Region: North America
• Stock Exchange: NYSEARCA
• Ticker Symbol: SBIO
• ETF Provider: SS&C
• Index Tracked: S-Network Medical Breakthroughs Index

Top 10 Holdings

31.67% of assets

Name	Symbol	Weight
Kymera Therapeutics, Inc.	KYMR	4.15%
Mirum Pharmaceuticals, Inc.	MIRM	3.44%
CG Oncology, Inc.	CGON	3.41%
Alkermes plc	ALKS	3.32%
Celcuity Inc.	CELC	3.24%
Apellis Pharmaceuticals, Inc.	APLS	3.12%
Xenon Pharmaceuticals Inc.	XENE	2.91%
Apogee Therapeutics, Inc.	APGE	2.89%
Amicus Therapeutics, Inc.	FOLD	2.72%
Crinetics Pharmaceuticals, Inc.	CRNX	2.47%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 19, 2024	$1.17346	Dec 26, 2024
Dec 21, 2023	$0.07106	Dec 27, 2023
Dec 19, 2019	$0.01585	Dec 27, 2019
Dec 20, 2018	$0.7841	Dec 27, 2018
Dec 21, 2017	$0.57949	Dec 28, 2017

Performance

SBIO had a total return of 113.53% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.76%.